Why Did Eli Lilly Stock Slide 6% Despite Strong GLP-1 Momentum? [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
driven by itsblockbuster tirzepatide (GLP-1) injections, Mounjaro for type II diabetes (T2D) and Zepbound for obesity. Despite being on the market for just over three years, both products have delivered exceptional sales growth as demand for GLP-1 therapies has surged worldwide. Together, these medicines now account for more than half of Lilly's total revenues, underscoring how central the franchise has become to the company's growth story. However, Lilly's shares fell about 5.9% on Tuesday after HSBC reportedly downgraded the rating on the stock and lowered its price target. The investment bank flagged potential pricing pressure, rising competition in the obesity drug market and the possibility that long-term revenue expectations for GLP-1 drugs may be overly optimistic. Another overhang is the continued availability of compounded versions of tirzepatide in certain channels despite the FDA's crackdown, which could temper demand for Lilly's branded therapies. Eli Lilly's primary r
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (LLY) Announces Positive Topline Results From the Phase 3 ADorable-1 Trial [Yahoo! Finance]Yahoo! Finance
- LLY's Next-Gen Obesity Drug Meets Goal in First Phase III Study for T2D [Yahoo! Finance]Yahoo! Finance
- Lilly GLP-1 drug rivals Novo's pipeline treatment on gut side effects but throws up skin concern [Yahoo! Finance]Yahoo! Finance
- RBC Capital Sees Eli Lilly's (LLY) Retatrutide as Key Growth Driver despite Mixed Trial Results [Yahoo! Finance]Yahoo! Finance
- Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 3/20/26 - Form DEFA14A
- 3/20/26 - Form DEF
- 3/17/26 - Form 4
- LLY's page on the SEC website